佐力药业：拟3.56亿元收购未来医药多种微量元素注射液资产组

Core Viewpoint - Zhaoli Pharmaceutical has signed an asset acquisition agreement to purchase a variety of trace element injection assets from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, including tax [1] Group 1: Acquisition Details - The acquisition includes the research and production technical data, marketing approvals, trademarks, patents, contractual rights and obligations, and employee labor relations related to the products [1] - The asset group consists of the already marketed products "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", as well as the in-development product "Multiple Trace Element Injection (III)" [1]